These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 30506321)

  • 1. Isocitrate dehydrogenase gene mutations and 2-hydroxyglutarate accumulation in esophageal squamous cell carcinoma.
    Miyake K; Baba Y; Ishimoto T; Hiyoshi Y; Iwatsuki M; Miyamoto Y; Yoshida N; Watanabe M; Ogata Y; Nagayama M; Silsirivanit A; Kobayashi D; Araki N; Baba H
    Med Oncol; 2018 Nov; 36(1):11. PubMed ID: 30506321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.
    Dang L; White DW; Gross S; Bennett BD; Bittinger MA; Driggers EM; Fantin VR; Jang HG; Jin S; Keenan MC; Marks KM; Prins RM; Ward PS; Yen KE; Liau LM; Rabinowitz JD; Cantley LC; Thompson CB; Vander Heiden MG; Su SM
    Nature; 2009 Dec; 462(7274):739-44. PubMed ID: 19935646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isocitrate Dehydrogenase Mutations in Cancer: Mechanisms of Transformation and Metabolic Liability.
    Gunn K; Losman JA
    Cold Spring Harb Perspect Med; 2024 May; 14(5):. PubMed ID: 38191174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible.
    Losman JA; Looper RE; Koivunen P; Lee S; Schneider RK; McMahon C; Cowley GS; Root DE; Ebert BL; Kaelin WG
    Science; 2013 Mar; 339(6127):1621-5. PubMed ID: 23393090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IDH1 mutation produces R-2-hydroxyglutarate (R-2HG) and induces mir-182-5p expression to regulate cell cycle and tumor formation in glioma.
    Zhao H; Meng L; Du P; Liao X; Mo X; Gong M; Chen J; Liao Y
    Biol Res; 2024 May; 57(1):30. PubMed ID: 38760850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives.
    Yang H; Ye D; Guan KL; Xiong Y
    Clin Cancer Res; 2012 Oct; 18(20):5562-71. PubMed ID: 23071358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia.
    DiNardo CD; Propert KJ; Loren AW; Paietta E; Sun Z; Levine RL; Straley KS; Yen K; Patel JP; Agresta S; Abdel-Wahab O; Perl AE; Litzow MR; Rowe JM; Lazarus HM; Fernandez HF; Margolis DJ; Tallman MS; Luger SM; Carroll M
    Blood; 2013 Jun; 121(24):4917-24. PubMed ID: 23641016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exceptionally rare IDH1-mutant adult medulloblastoma with concurrent GNAS mutation revealed by in vivo magnetic resonance spectroscopy and deep sequencing.
    Liserre R; Branzoli F; Pagani F; Gryzik M; Cominelli M; Miele E; Marjańska M; Doglietto F; Poliani PL
    Acta Neuropathol Commun; 2023 Mar; 11(1):47. PubMed ID: 36941703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating Oncometabolite 2-hydroxyglutarate as a Potential Biomarker for Isocitrate Dehydrogenase (IDH1/2) Mutant Cholangiocarcinoma.
    Lee CL; O'Kane GM; Mason WP; Zhang WJ; Spiliopoulou P; Hansen AR; Grant RC; Knox JJ; Stockley TL; Zadeh G; Chen EX
    Mol Cancer Ther; 2024 Mar; 23(3):394-399. PubMed ID: 38015561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Roles of the oncometabolite enantiomers of 2-hydroxyglutarate and their metabolism by diverse dehydrogenases.
    Garcia I; Cornely K; Peterson CN; Berkmen MB
    Essays Biochem; 2024 Jun; ():. PubMed ID: 38919140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Noninvasive Quantification of 2-Hydroxyglutarate in Human Gliomas with IDH1 and IDH2 Mutations.
    Emir UE; Larkin SJ; de Pennington N; Voets N; Plaha P; Stacey R; Al-Qahtani K; Mccullagh J; Schofield CJ; Clare S; Jezzard P; Cadoux-Hudson T; Ansorge O
    Cancer Res; 2016 Jan; 76(1):43-9. PubMed ID: 26669865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A high-throughput fluorimetric assay for 2-hydroxyglutarate identifies Zaprinast as a glutaminase inhibitor.
    Elhammali A; Ippolito JE; Collins L; Crowley J; Marasa J; Piwnica-Worms D
    Cancer Discov; 2014 Jul; 4(7):828-39. PubMed ID: 24740997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic dysregulation in cancers by isocitrate dehydrogenase 2 (IDH2).
    Nayarisseri A; Bandaru S; Khan A; Sharma K; Bhrdwaj A; Kaur M; Ghosh D; Chopra I; Panicker A; Kumar A; Saravanan P; Belapurkar P; Mendonça Junior FJB; Singh SK
    Adv Protein Chem Struct Biol; 2024; 141():223-253. PubMed ID: 38960475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. (R)-2-Hydroxyglutarate Inhibits KDM5 Histone Lysine Demethylases to Drive Transformation in IDH-Mutant Cancers.
    Gunn K; Myllykoski M; Cao JZ; Ahmed M; Huang B; Rouaisnel B; Diplas BH; Levitt MM; Looper R; Doench JG; Ligon KL; Kornblum HI; McBrayer SK; Yan H; Duy C; Godley LA; Koivunen P; Losman JA
    Cancer Discov; 2023 Jun; 13(6):1478-1497. PubMed ID: 36847506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural and synthetic 2-oxoglutarate derivatives are substrates for oncogenic variants of human isocitrate dehydrogenase 1 and 2.
    Liu X; Reinbold R; Liu S; Herold RA; Rabe P; Duclos S; Yadav RB; Abboud MI; Thieffine S; Armstrong FA; Brewitz L; Schofield CJ
    J Biol Chem; 2023 Feb; 299(2):102873. PubMed ID: 36621625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate.
    Andronesi OC; Arrillaga-Romany IC; Ly KI; Bogner W; Ratai EM; Reitz K; Iafrate AJ; Dietrich J; Gerstner ER; Chi AS; Rosen BR; Wen PY; Cahill DP; Batchelor TT
    Nat Commun; 2018 Apr; 9(1):1474. PubMed ID: 29662077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of 2-Hydroxyglutarate by 3.0-Tesla Magnetic Resonance Spectroscopy in Gliomas with Rare IDH Mutations: Making Sense of "False-Positive" Cases.
    Natsumeda M; Igarashi H; Gabdulkhaev R; Takahashi H; Motohashi K; Ogura R; Watanabe J; Tsukamoto Y; Okamoto K; Kakita A; Nakada T; Fujii Y
    Diagnostics (Basel); 2021 Nov; 11(11):. PubMed ID: 34829476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolism, Activity, and Targeting of D- and L-2-Hydroxyglutarates.
    Ye D; Guan KL; Xiong Y
    Trends Cancer; 2018 Feb; 4(2):151-165. PubMed ID: 29458964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differentiating Inhibition Selectivity and Binding Affinity of Isocitrate Dehydrogenase 1 Variant Inhibitors.
    Liu S; Abboud M; Mikhailov V; Liu X; Reinbold R; Schofield CJ
    J Med Chem; 2023 Apr; 66(7):5279-5288. PubMed ID: 36952395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An effective two-stage NMBzA-induced rat esophageal tumor model revealing that the FAT-Hippo-YAP1 axis drives the progression of ESCC.
    Zheng W; Yuan H; Fu Y; Deng G; Zheng X; Xu L; Fan H; Jiang W; Yu X
    Cancer Lett; 2024 Apr; 588():216813. PubMed ID: 38499266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.